<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01774617</url>
  </required_header>
  <id_info>
    <org_study_id>HHL/UFRJ-04</org_study_id>
    <secondary_id>CAAE 06343212.8.0000.5257</secondary_id>
    <nct_id>NCT01774617</nct_id>
  </id_info>
  <brief_title>Comparative Analysis of Different Tests to Evaluate Prognosis of Patients on Liver Transplant Waiting List</brief_title>
  <official_title>Comparative Analysis of Indocyanine Green Clearance Test, MELD Score, MELD-Na Score, Transient Elastography and Hepatic Venous Pressure Gradient to Evaluate Prognosis of Patients on Liver Transplant Waiting List</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guilherme Rezende</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rio de Janeiro State Research Supporting Foundation (FAPERJ)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidade Federal do Rio de Janeiro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a cohort to evaluate the power of different diagnostic tests in predicting the&#xD;
      prognosis of patients with severe liver disease.&#xD;
&#xD;
      Patients with decompensated liver cirrhosis on the waiting list for liver transplantation&#xD;
      will be evaluated with comparison of different diagnostic tests according to the MELD score&#xD;
      (Model for End-Stage Liver Disease), MELD-Na (Model for End-Stage Liver Disease and sodium),&#xD;
      indocyanine green clearance test, hepatic venous pressure gradient and transient&#xD;
      elastography. All patients will be submitted to all the tests and prospectively followed for&#xD;
      6 months, to establish mortality and complications related to liver disease in order to&#xD;
      define the value of each method to predict outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">November 2018</completion_date>
  <primary_completion_date type="Actual">November 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>6 months</time_frame>
    <description>Mortality within 6 months after evaluation, classifying as related or non-related to liver disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chronic liver failure and portal hypertension complications</measure>
    <time_frame>6 months</time_frame>
    <description>Complications:&#xD;
gastroesophageal variceal bleeding&#xD;
worsening of hepatic encephalopathy&#xD;
decompensated ascites and spontaneous bacterial peritonitis&#xD;
hepatorenal syndrome</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">80</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Liver Failure</condition>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>Patients with advanced liver disease</arm_group_label>
    <description>Inclusion criteria are diagnosis of cirrhosis with portal hypertension detected by abdominal ultrasound with color Doppler flowmetry or upper digestive endoscopy. Exclusion criteria were age 18 or older, previous contrast allergy, hepatocellular carcinoma or any malignancy except basocellular carcinoma, renal failure (creatinine level &gt;1.5 mg/dL), severe bleeding disorder (prothrombin activity test &lt; 30% or platelets count &lt;35,000/mcL) or decompensated cirrhosis characterized by severe ascites or grade II or higher encephalopathy. Patients with alcoholic cirrhosis should be abstinent for at least six months.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Cirrhotic patients on the liver transplantation waiting list of a single center.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  the study includes patients (80 patients)&#xD;
&#xD;
          -  were male and female&#xD;
&#xD;
          -  aged between 18 and 69 years with chronic liver disease&#xD;
&#xD;
          -  with MELD inclusion greater than or equal to 14 to 30&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  they have been transplanted&#xD;
&#xD;
          -  have a diagnosis of primary malignant liver (HCC) signed by imaging tests performed&#xD;
&#xD;
          -  MELD scores greater than 30.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guilherme FM Rezende, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universidade Federal do Rio de Janeiro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universit√°rio Clementino Fraga Filho / Federal University of Rio de Janeiro</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>21941-913</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 22, 2013</study_first_submitted>
  <study_first_submitted_qc>January 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2013</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal do Rio de Janeiro</investigator_affiliation>
    <investigator_full_name>Guilherme Rezende</investigator_full_name>
    <investigator_title>Associate Professor, MD PhD</investigator_title>
  </responsible_party>
  <keyword>portal hypertension</keyword>
  <keyword>elastography</keyword>
  <keyword>Hepatic venous pressure gradient measurement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

